Clinical Trials on Relapsed/Refractory Waldenstrom Macroglobulinemia in China

Total 330 results

BeiGene

Recruiting

Study to Evaluate the Efficacy and Safety of BGB-11417 in Participants With Waldenström's Macroglobulinemia

Waldenstrom Macroglobulinemia | Waldenstrom's Macroglobulinemia Recurrent | Waldenstrom's Macroglobulinemia Refractory

United States, Australia, France, China, Spain, United Kingdom
Beijing InnoCare Pharma Tech Co., Ltd.

Completed

A Study of ICP-022 in the Treatment of Recurrent or Refractory Waldenstrom Macroglobulinemia

Waldenstrom's Macroglobulinemia Recurrent | Waldenstrom's Macroglobulinemia Refractory

China
Institute of Hematology & Blood Diseases Hospital

Unknown

The Comparison of RCD Versus BCD in Newly Diagnosed Waldenström Macroglobulinemia (BDH-WM01)

Waldenström Macroglobulinemia

China
Institute of Hematology & Blood Diseases Hospital

Unknown

The Efficacy of TCD Following by TP Maintenance Therapy in Newly Diagnosed WM (BDH-WM02)

Waldenström Macroglobulinemia

China
Institute of Hematology & Blood Diseases Hospital

Recruiting

Zanubrutinib, Ixazomib and Dexamethasone in Patients With Treatment Naive Waldenstrom's Macroglobulinemia

Waldenström Macroglobulinemia

China
Institute of Hematology & Blood Diseases Hospital

Unknown

Comparison of ASCT and Conventional Chemotherapy in High Risk Waldenström Macroglobulinemia (BDH-WM03)

Waldenström Macroglobulinemia

China
Centaurus Biopharma Co., Ltd.

Unknown

Study of Safety,Efficacy and Pharmacokinetics of CT-1530 in Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom's Macroglobulinemia

Chronic Lymphocytic Leukemia | Waldenstrom's Macroglobulinemia | Diffuse Large B Cell Lymphoma | Relapsed or Refractory B Cell Non-Hodgkin Lymphoma | Mantle Zone Lymphoma Refractory/Recurrent | Follicle Centre Lymphoma Diffuse

China
Shanghai Changzheng Hospital
RenJi Hospital; Huashan Hospital; Shanghai 6th People's Hospital; Huadong Hospital

Recruiting

A Phase 2 Clinical Trial to Evaluate Zanubrutinib Combined With BR (Bendamustine/Rituximab) Regimen in Subjects With Newly-diagnosed Waldenström's Macroglobulinemia (CZ-WM01)

Waldenström's Macroglobulinemia

China
BeiGene

Completed

Study of BTK Inhibitor BGB-3111 in Chinese Subjects With Relapsed/Refractory Waldenström's Macroglobulinemia (WM)

Waldenström's Macroglobulinemia (WM)

China
Institute of Hematology & Blood Diseases Hospital

Recruiting

Zanubrutinib Plus BR in Newly Diagnosed Symptomatic WM (ZBR)

Waldenstrom Macroglobulinemia

China
Merck Sharp & Dohme LLC

Recruiting

Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)

Non-Hodgkins Lymphoma | Hematologic Malignancies | Chronic Lymphocytic Leukaemia | Waldenstroms Macroglobulinaemia

Poland, United States, Argentina, Australia, Brazil, Canada, France, Israel, Italy, Spain, Switzerland, Turkey, United Kingdom, Korea, Republic of, Germany, Denmark, China, Romania, Czechia, Hungary, Ireland, Ukraine
The First Affiliated Hospital of Soochow University

Unknown

PCD Versus RCD for the Treatment of Patients With Waldenstrom's Macroglobulinemia

Treatment

China
Janssen Research & Development, LLC

Completed

A Study of Ibrutinib (PCI-32765) in Chinese Participants With Relapse or Refractory Waldenstrom's Macroglobulinemia (WM)

Waldenstrom Macroglobulinemia

China
Minghui Pharmaceutical (Shanghai) LTD

Recruiting

This is a Phase 1 Study of MH048 in Patients With Selected Relapsed/Refractory B-cell Malignancies

Relapsed/Refractory B-cell Malignancies

China
Xinxiang medical university

Recruiting

NKG2D-CAR-NK92 Cells Immunotherapy for Solid Tumors

Relapsed/Refractory Solid Tumors

China
Cancer Institute and Hospital, Chinese Academy...

Recruiting

Single Arm Clinical Study on the Safety and Efficacy of Personalized KSX01-TCRT in Patients With Advanced Solid Tumors

Refractory Solid Tumors | Relapsed Solid Tumors

China
Apollomics Inc.
Zhejiang CrownMab Biotech Co. Ltd

Recruiting

Study to Evaluate PK and Safety With Uproleselan Combined With Chemotherapy to Treat Chinese R/R AML Patients

Relapsed/Refractory AML

China
Fujian Medical University

Unknown

CD123/CLL1 CAR-T Cells for R/R AML (STPHI_0001)

Relapsed/Refractory AML

China
Apollomics Inc.
Zhejiang CrownMab Biotech Co. Ltd

Recruiting

Study to Evaluate the Efficacy of Uproleselan in Combination With Chemotherapy in Chinese Patients With R/R AML

Relapsed/Refractory AML

China
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Anhui Provincial Hospital

Not yet recruiting

UTAA09 Injection in the Treatment of Relapsed/Refractory Hematolymphatic Malignancies.

CD19-positive Relapsed or Refractory B-cell Malignancies

China
EdiGene (GuangZhou) Inc.
The First Affiliated Hospital of Henan University of Science and Technology

Active, not recruiting

A Study of ET-02 in Patients With Relapsed or Refractory B-cell Malignancy(NHL/ALL)

Relapsed or Refractory B-cell Malignancy(NHL/ALL)

China
BeiGene

Recruiting

Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader

Follicular Lymphoma | Waldenström Macroglobulinemia | Mantle Cell Lymphoma | Marginal Zone Lymphoma | Non-Hodgkin Lymphoma | B-cell Malignancy | Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | Richter's Transformation | DLBCL Unclassifiable

China
Ascentage Pharma Group Inc.

Recruiting

APG-2575 Single Agent or in Combination With Ibrutinib or Rituximab in Patients With Waldenström Macroglobulinemia (MAPLE-1)

Waldenstrom Macroglobulinemia

United States, China, Australia
Janssen Pharmaceutical K.K.

Completed

A Study of Ibrutinib in Combination With Rituximab, in Japanese Participants With Waldenstrom's Macroglobulinemia (WM)

Waldenstrom Macroglobulinemia

Japan
The Affiliated Hospital of the Chinese Academy...
Chinese PLA General Hospital

Unknown

Allogeneic CART-33 for Relapsed/Refractory CD33+ AML

Relapsed and/or Refractory CD33+ AML

China
Haisco Pharmaceutical Group Co., Ltd.

Recruiting

A Study of HSK29116 in Adults With Relapsed/Refractory B-cell Malignancies

Relapsed/Refractory B-Cell Malignancies

China, Australia
TCRx Therapeutics Co.Ltd

Recruiting

KSX01-TCRT Injection Project in Solid Tumors

Refractory Solid Tumors | Relapsed Solid Tumors | TCR-T Cells

China
The First Affiliated Hospital of Soochow University

Not yet recruiting

Selinexor and HAAG With/Without HMA in Relapsed/Refractory Acute Leukemia (AML) Patients

Relapsed/Refractory AML

China
Shanghai General Hospital, Shanghai Jiao Tong University...

Recruiting

CLL-1 CAR-NK Cells for Relapsed/Refractory AML

Relapsed Adult AML | Refractory AML

China
Hrain Biotechnology Co., Ltd.
Shanghai Changzheng Hospital

Active, not recruiting

Anti-CD19/BCMA Bispecific CAR-T Cell Therapy for R/R POMES

POMES Syndrome | Relapsed and Refractory POMES Syndrome

China
Fujian Medical University

Unknown

CART-19 Cells For R/R B-ALL (CCFRRBA)

Relapsed/Refractory B-cell ALL

China
TCRx Therapeutics Co.Ltd

Recruiting

KSH01-TCRT Solid Tumors (KSH01-TCRT)

Refractory Solid Tumors | Relapsed Solid Tumors | TCR-T Cells

China
Hebei Yanda Ludaopei Hospital
China Immunotech (Beijing) Biotechnology Co., Ltd.

Terminated

CD19/CD22-Dual-STAR-T for Patients With B Cell Acute Leukemia(B-ALL)

Refractory and Relapsed B Cell Acute Leukemia

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Recruiting

A Study of TQ-B3525 on Tolerance and Pharmacokinetics

Relapsed or Refractory Lymphoma or Advanced Cancer

China
Innovent Biologics (Suzhou) Co. Ltd.

Recruiting

Intense Monitoring Study on Tyvyt

Relapsed or Refractory Classical Hodgkin's Lymphoma

China
Beijing Boren Hospital

Terminated

A Study of OVV-01 Injection in Combination With IBR900 Cell Injection in Patients With Advanced Malignant Tumors

Advanced Solid Tumor | Relapsed/Refractory Lymphoma

China
Zhejiang University
Yake Biotechnology Ltd.

Recruiting

CAR-T Cells Combined With Dasatinib for Patients With Relapsed and/or Refractory B-cell Hematological Malignancies

Acute Lymphoblastic Leukemia, in Relapse | Multiple Myeloma in Relapse | Multiple Myeloma, Refractory | Non-Hodgkin's Lymphoma, Relapsed | Non-Hodgkin's Lymphoma Refractory | Acute Lymphocytic Leukaemia Refractory

China
Institute of Hematology & Blood Diseases Hospital
Juventas Cell Therapy Ltd.

Available

A Clinical Study of CAR-T Cells in the Treatment of Relapsed and Refractory Hematological Malignancies

Relapsed and Refractory Hematological Malignancies

China
The First Affiliated Hospital of Xiamen University
Fujian Cancer Hospital; Dongguan People's Hospital; Huizhou Municipal Central... and other collaborators

Recruiting

Venetoclax Combining Chidamide and Azacitidine (VCA) in the Treatment of R/R AML

Leukemia, Myeloid, Acute | Refractory Leukemia | Relapsed Adult AML

China
The First Affiliated Hospital of Soochow University

Recruiting

Study of Selinexor Combined With Chidamide in Relapsed/Refractory Acute Leukemia (AML) Patients

Acute Myeloid Leukemia (Relapsed/Refractory)

China
Shandong University
Juventas Cell Therapy Ltd.

Unknown

A Clinical Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Injection (CNCT19) in the Treatment of Cluster of Differentiation 19 (CD19) Positive Relapsed or Refractory B Cell Malignancies

Relapsed or Refractory Hematological Malignancies

China
Sinocelltech Ltd.

Recruiting

A Clinical Study of SCTC21C in Participants With CD38+ Hematologic Malignancies

Relapsed or Refractory Hematologic Malignancies

China
Second Affiliated Hospital of Xi'an Jiaotong University
Nanjing Legend Biotech Co.

Terminated

Study Evaluating Safety and Efficacy of CAR-T Cells Targeting CD123 in Patients With Acute Leukemia

Acute Myeloid Leukemia | Acute Leukemia | Acute Leukemia in Relapse | Relapsed or Refractory Acute Leukemia

China
Affiliated Hospital to Academy of Military Medical...
Beijing JD Biotech Co. LTD.

Recruiting

CAR-NK Targeted CD19 for r/r B-cell Malignancies

Adult Relapsed/Refractory B-cell Hematologic Malignancies

China
Qilu Puget Sound Biotherapeutics (dba Sound Biologics)

Recruiting

PSB202 in Patients With Previously Treated-, Relapsed-, Indolent B-Cell Malignancies

Follicular Lymphoma | Waldenstrom Macroglobulinemia | Mantle Cell Lymphoma | Marginal Zone Lymphoma | MALT Lymphoma | Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | Indolent Lymphoma | Refractory B-Cell Lymphoma

United States, Australia, China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Recruiting

A Study of TQB3473 Tablets in Subjects With Relapsed or Refractory Hematological Malignancies

Relapsed/Refractory Hematological Malignancies

China
Shenzhen BinDeBio Ltd.
The First Affiliated Hospital of Zhengzhou University

Unknown

A Clinical Study Evaluating the Safety and Efficacy of BinD19 Treatment in R/R ALL and Lymphoma Subjects

Refractory B-cell Acute Lymphoblastic Leukemia | Relapsed B-cell Acute Lymphoblastic Leukemia | Relapsed／Refractory B-cell Lymphoma

China
He Huang
Yake Biotechnology Ltd.

Recruiting

A Study of CD20/CD22 Targeted CAR T-cell Therapy for Relapsed or Refractory Lymphoid Malignancies

Relapsed and Refractory | Lymphoid Hematological Malignancies

China
Chinese PLA General Hospital

Recruiting

CAR-T-19 Cells for Patients With CD19+ Relapse/Refractory B-ALL

CD19+ Relapse/Refractory B-ALL

China
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Peking University People's Hospital; The First Affiliated Hospital of Zhengzhou... and other collaborators

Recruiting

PA3-17 Injection Treatment of Adult Patients With CD7-positive Relapsed/Refractory Lymphoid Hematologic Malignancies

CD7-positive Relapsed/Refractory Lymphoid Hematologic Malignancies

China

Clinical Trials on Relapsed/Refractory Waldenstrom Macroglobulinemia in China

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Chile

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations